Coherus BioSciences Inc (CHRS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.35 (+9.76%), Market cap $0.29B, 52-week low–high $0.72 ~ $2.51.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It ha
Financial statements, price targets, institutional (13F) holdings and related news for Coherus BioSciences Inc are updated in real time on BlackAll Trade.
Coherus BioSciences Inc trades at $1.35 (+9.76%). Real-time quotes and charts are available on BlackAll Trade.
Coherus BioSciences Inc has a market cap of about $0.29B.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulas